Anixa Biosciences

ANIX · NASDAQ

$2.68+$0.07 (+2.68%)TodayMarket closed · Oct 20, 7:37 PM ET

Prev close $2.61

ANIX analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $9.94 (+271.1% upside)

Low: $6.06
Now: $2.68
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

ANIX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 22, 2026	Maintains	Buy	$7.00 → $6.00	40%
D. Boral Capital	Jun 30, 2026	Initiates	Buy	$10.00	29%
D. Boral Capital	Apr 8, 2026	Maintains	Buy	$10.00	29%
D. Boral Capital	Mar 31, 2026	Maintains	Buy	$10.00	29%
D. Boral Capital	Feb 4, 2026	Maintains	Buy	$10.00	29%
D. Boral Capital	Dec 12, 2025	Maintains	Buy	$10.00	29%

The case for and against

Updated Sep 24, 2026

Bull case

Anixa Biosciences is a promising biotechnology company with a strong focus on developing innovative therapies and vaccines to address critical unmet needs in oncology. The company's portfolio includes potential treatments for high-incidence and hard-to-treat cancers such as breast, ovarian, lung, colon, and prostate. Recent updates, including the strengthening of its global patent estate for the breast cancer vaccine and the positive results from the Phase 1 trial of the CAR-T therapy for ovarian cancer, provide evidence of the company's progress and potential for future success. While there are risks involved, such as failure in clinical trials or securing regulatory approval, the potential market value of the company is estimated at $254M, and our Buy rating is reaffirmed with a 12-month price target of $6 per share.

Bear case

Anixa Biosciences is facing challenges in its early stage cancer vaccine programs, which are its main focus. With limited financial resources and no significant revenues, the company will struggle to fund these programs effectively. The conference appearance may provide temporary interest and support, but ultimately long-term results will be necessary to justify investment in the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.